Illuccix®, kit for the preparation of 68Ga-PSMA-11 Injection, offers both clinical and practice-related support1,4,5
National Comprehensive Cancer Network (NCCN) Guidelines and Society of Nuclear Medicine and Molecular Imaging (SNMMI) appropriate use criteria recommendations include 68Ga-PSMA-11 PET/CT or PET/MRI across different stages of prostate cancer7,8,a
aThese guidelines do not recommend use of a particular radiopharmaceutical.
Diagnostic performance demonstrated across prostate cancer stages in clinical trials1
BCR, biochemical recurrence; mCRPC, metastatic castration-resistant prostate cancer; nmCRPC, nonmetastatic castration-resistant prostate cancer; PCa, prostate cancer; PSA, prostate-specific antigen.
Early detection and accurate assessment of prostate cancer are crucial across prostate cancer stages as they are often essential for determining treatment decisions.7,8
Mechanism of Action
68Ga harnesses the power of PSMA PET/CT
PSMA has become a major breakthrough in prostate cancer diagnostics and the growing field of nuclear medicine.3,9 PSMA is overexpressed in primary and metastatic prostate cancer cells, but its expression is low or absent in healthy cells, which makes PSMA an ideal target for prostate cancer imaging3,9,10:
- More than 90% of primary lesions show moderate to high PSMA expression11
- Higher PSMA levels are associated with advanced disease and increased PSA levels3
68Ga-PSMA-11 is a radiotracer that binds with high affinity to PSMA and in doing so can reveal prostate cancer cells in the body.3
Important Safety Information
The safety of gallium Ga 68 gozetotide was evaluated in 960 patients, each receiving one dose of gallium Ga 68 gozetotide. The average injected activity was 188.7 ± 40.7 MBq (5.1 ± 1.1 mCi). No serious adverse reactions were attributed to gallium Ga 68 gozetotide. The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of < 1%.
Please see additional Important Safety Information below.
Please see full Prescribing Information.
Well-established and reliable national distribution network
68Ga is a widely accessible radioisotope for PSMA PET imaging
68Ga is a widely available radioisotope that can be accessed through a nationwide distribution network of generators and cyclotrons, including those within major academic centers and community health systems. 68Ga extends the reach of PSMA imaging to enable people throughout the United States to benefit from this important technology.5
68Ga delivers the flexibility of either high-volume production (via cyclotrons) or on-site, on-demand production (via generators) that may enhance the efficiency of day-to-day workflow4,5
- Ability to fill STAT orders and accommodate patient schedule changes4
- Flexibility to image patients throughout the day, even on short notice4
- Well-established distribution network for an efficient administrative and purchasing process5